Intraocular pressure changes during intravitreal aflibercept injection based on treat-and-extend regimen in Japanese patients with neovascular age-related macular degeneration and glaucoma
Purpose To assess the changes in intraocular pressure (IOP) after intravitreal aflibercept injections in Japanese patients with neovascular age-related macular degeneration (nAMD) complicated by glaucoma. Study design Retrospective observational study. Methods We retrospectively reviewed 27 eyes of...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of ophthalmology 2024-03, Vol.68 (2), p.91-95 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 95 |
|---|---|
| container_issue | 2 |
| container_start_page | 91 |
| container_title | Japanese journal of ophthalmology |
| container_volume | 68 |
| creator | Honjo, Junichiro Mukai, Ryo Itagaki, Kanako Tanaka, Keiichiro Norikawa, Koki Kato, Yutaka Kasai, Akihito Sugano, Yukinori Sekiryu, Tetsuju |
| description | Purpose
To assess the changes in intraocular pressure (IOP) after intravitreal aflibercept injections in Japanese patients with neovascular age-related macular degeneration (nAMD) complicated by glaucoma.
Study design
Retrospective observational study.
Methods
We retrospectively reviewed 27 eyes of 25 Japanese patients diagnosed with nAMD complicated by glaucoma. The patients were treated with 2 mg/0.05 ml of aflibercept and followed for 52 weeks according to a treat-and-extend (TAE) regimen after 3 consecutive monthly injections. The IOP of each eye was measured at each visit using non-contact tonometry. IOP changes as well as additional glaucoma treatments during 52 weeks were recorded.
Results
The mean of aflibercept injections was 8.3 ± 1.9. The mean IOP at baseline was 14.0 ± 3.1 mmHg, and the mean IOP after aflibercept therapy was 13.0 ± 2.4 mmHg at the final visit (
P
= 0.0463). No patients received additional glaucoma treatment of eye drops or surgery.
Conclusion
Our results suggest that intravitreal aflibercept injections may be beneficial for patients with nAMD complicated by glaucoma. |
| doi_str_mv | 10.1007/s10384-023-01041-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2922947493</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2985943087</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-d1a1db4576af09f9eaaf58022b5822883c9bf98dcfa77e7d48646541bd7e39dd3</originalsourceid><addsrcrecordid>eNp9kctu1TAQhi0EoofCC7BAltiwMfiWxFmiiktRJTawjib2JPVR4gTbaeHdeDh8mgISC1a2PJ-_mdFPyHPBXwvOmzdJcGU041IxLrgWTD0gB1ELxaTU9UNy4FwKVomqOiNPUjpyzrVU8jE5U0aJuuHqQH5ehhxhsdsEka4RU9oiUnsNYcRE3RZ9GKk_MTc-R4SJwjD5HqPFNZfCEW32S6A9JHS0XE5QZhAcw-8Zg6MRRz9jKCz9BCsETEhXyB5DTvTW52sacLmBtI8AI7KIE-Rim2F_czhiwAh3jYqZjhNsdpnhKXk0wJTw2f15Tr6-f_fl4iO7-vzh8uLtFbNK1pk5AcL1umpqGHg7tAgwVIZL2VdGSmOUbfuhNc4O0DTYOG1qXVda9K5B1Tqnzsmr3bvG5duGKXezTxanqWyzbKmTrZStbnSrCvryH_S4bDGU6QplqlYrbppCyZ2ycUkp4tCt0c8Qf3SCd6dsuz3brmTb3WXbndQv7tVbP6P78-V3mAVQO5DWU2wY__b-j_YXcMa0Zg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2985943087</pqid></control><display><type>article</type><title>Intraocular pressure changes during intravitreal aflibercept injection based on treat-and-extend regimen in Japanese patients with neovascular age-related macular degeneration and glaucoma</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Honjo, Junichiro ; Mukai, Ryo ; Itagaki, Kanako ; Tanaka, Keiichiro ; Norikawa, Koki ; Kato, Yutaka ; Kasai, Akihito ; Sugano, Yukinori ; Sekiryu, Tetsuju</creator><creatorcontrib>Honjo, Junichiro ; Mukai, Ryo ; Itagaki, Kanako ; Tanaka, Keiichiro ; Norikawa, Koki ; Kato, Yutaka ; Kasai, Akihito ; Sugano, Yukinori ; Sekiryu, Tetsuju</creatorcontrib><description>Purpose
To assess the changes in intraocular pressure (IOP) after intravitreal aflibercept injections in Japanese patients with neovascular age-related macular degeneration (nAMD) complicated by glaucoma.
Study design
Retrospective observational study.
Methods
We retrospectively reviewed 27 eyes of 25 Japanese patients diagnosed with nAMD complicated by glaucoma. The patients were treated with 2 mg/0.05 ml of aflibercept and followed for 52 weeks according to a treat-and-extend (TAE) regimen after 3 consecutive monthly injections. The IOP of each eye was measured at each visit using non-contact tonometry. IOP changes as well as additional glaucoma treatments during 52 weeks were recorded.
Results
The mean of aflibercept injections was 8.3 ± 1.9. The mean IOP at baseline was 14.0 ± 3.1 mmHg, and the mean IOP after aflibercept therapy was 13.0 ± 2.4 mmHg at the final visit (
P
= 0.0463). No patients received additional glaucoma treatment of eye drops or surgery.
Conclusion
Our results suggest that intravitreal aflibercept injections may be beneficial for patients with nAMD complicated by glaucoma.</description><identifier>ISSN: 0021-5155</identifier><identifier>EISSN: 1613-2246</identifier><identifier>DOI: 10.1007/s10384-023-01041-3</identifier><identifier>PMID: 38316703</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Age ; Age related diseases ; Angiogenesis Inhibitors ; Clinical Investigation ; Eye ; Eye diseases ; Glaucoma ; Glaucoma - drug therapy ; Humans ; Intraocular Pressure ; Intravitreal Injections ; Japan - epidemiology ; Macular degeneration ; Macular Degeneration - drug therapy ; Medicine ; Medicine & Public Health ; Observational studies ; Ophthalmology ; Patients ; Ranibizumab - therapeutic use ; Receptors, Vascular Endothelial Growth Factor ; Recombinant Fusion Proteins - therapeutic use ; Retrospective Studies ; Vascular Endothelial Growth Factor A</subject><ispartof>Japanese journal of ophthalmology, 2024-03, Vol.68 (2), p.91-95</ispartof><rights>Japanese Ophthalmological Society 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. Japanese Ophthalmological Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-d1a1db4576af09f9eaaf58022b5822883c9bf98dcfa77e7d48646541bd7e39dd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10384-023-01041-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10384-023-01041-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38316703$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Honjo, Junichiro</creatorcontrib><creatorcontrib>Mukai, Ryo</creatorcontrib><creatorcontrib>Itagaki, Kanako</creatorcontrib><creatorcontrib>Tanaka, Keiichiro</creatorcontrib><creatorcontrib>Norikawa, Koki</creatorcontrib><creatorcontrib>Kato, Yutaka</creatorcontrib><creatorcontrib>Kasai, Akihito</creatorcontrib><creatorcontrib>Sugano, Yukinori</creatorcontrib><creatorcontrib>Sekiryu, Tetsuju</creatorcontrib><title>Intraocular pressure changes during intravitreal aflibercept injection based on treat-and-extend regimen in Japanese patients with neovascular age-related macular degeneration and glaucoma</title><title>Japanese journal of ophthalmology</title><addtitle>Jpn J Ophthalmol</addtitle><addtitle>Jpn J Ophthalmol</addtitle><description>Purpose
To assess the changes in intraocular pressure (IOP) after intravitreal aflibercept injections in Japanese patients with neovascular age-related macular degeneration (nAMD) complicated by glaucoma.
Study design
Retrospective observational study.
Methods
We retrospectively reviewed 27 eyes of 25 Japanese patients diagnosed with nAMD complicated by glaucoma. The patients were treated with 2 mg/0.05 ml of aflibercept and followed for 52 weeks according to a treat-and-extend (TAE) regimen after 3 consecutive monthly injections. The IOP of each eye was measured at each visit using non-contact tonometry. IOP changes as well as additional glaucoma treatments during 52 weeks were recorded.
Results
The mean of aflibercept injections was 8.3 ± 1.9. The mean IOP at baseline was 14.0 ± 3.1 mmHg, and the mean IOP after aflibercept therapy was 13.0 ± 2.4 mmHg at the final visit (
P
= 0.0463). No patients received additional glaucoma treatment of eye drops or surgery.
Conclusion
Our results suggest that intravitreal aflibercept injections may be beneficial for patients with nAMD complicated by glaucoma.</description><subject>Age</subject><subject>Age related diseases</subject><subject>Angiogenesis Inhibitors</subject><subject>Clinical Investigation</subject><subject>Eye</subject><subject>Eye diseases</subject><subject>Glaucoma</subject><subject>Glaucoma - drug therapy</subject><subject>Humans</subject><subject>Intraocular Pressure</subject><subject>Intravitreal Injections</subject><subject>Japan - epidemiology</subject><subject>Macular degeneration</subject><subject>Macular Degeneration - drug therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Observational studies</subject><subject>Ophthalmology</subject><subject>Patients</subject><subject>Ranibizumab - therapeutic use</subject><subject>Receptors, Vascular Endothelial Growth Factor</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Vascular Endothelial Growth Factor A</subject><issn>0021-5155</issn><issn>1613-2246</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu1TAQhi0EoofCC7BAltiwMfiWxFmiiktRJTawjib2JPVR4gTbaeHdeDh8mgISC1a2PJ-_mdFPyHPBXwvOmzdJcGU041IxLrgWTD0gB1ELxaTU9UNy4FwKVomqOiNPUjpyzrVU8jE5U0aJuuHqQH5ehhxhsdsEka4RU9oiUnsNYcRE3RZ9GKk_MTc-R4SJwjD5HqPFNZfCEW32S6A9JHS0XE5QZhAcw-8Zg6MRRz9jKCz9BCsETEhXyB5DTvTW52sacLmBtI8AI7KIE-Rim2F_czhiwAh3jYqZjhNsdpnhKXk0wJTw2f15Tr6-f_fl4iO7-vzh8uLtFbNK1pk5AcL1umpqGHg7tAgwVIZL2VdGSmOUbfuhNc4O0DTYOG1qXVda9K5B1Tqnzsmr3bvG5duGKXezTxanqWyzbKmTrZStbnSrCvryH_S4bDGU6QplqlYrbppCyZ2ycUkp4tCt0c8Qf3SCd6dsuz3brmTb3WXbndQv7tVbP6P78-V3mAVQO5DWU2wY__b-j_YXcMa0Zg</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Honjo, Junichiro</creator><creator>Mukai, Ryo</creator><creator>Itagaki, Kanako</creator><creator>Tanaka, Keiichiro</creator><creator>Norikawa, Koki</creator><creator>Kato, Yutaka</creator><creator>Kasai, Akihito</creator><creator>Sugano, Yukinori</creator><creator>Sekiryu, Tetsuju</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20240301</creationdate><title>Intraocular pressure changes during intravitreal aflibercept injection based on treat-and-extend regimen in Japanese patients with neovascular age-related macular degeneration and glaucoma</title><author>Honjo, Junichiro ; Mukai, Ryo ; Itagaki, Kanako ; Tanaka, Keiichiro ; Norikawa, Koki ; Kato, Yutaka ; Kasai, Akihito ; Sugano, Yukinori ; Sekiryu, Tetsuju</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-d1a1db4576af09f9eaaf58022b5822883c9bf98dcfa77e7d48646541bd7e39dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Age</topic><topic>Age related diseases</topic><topic>Angiogenesis Inhibitors</topic><topic>Clinical Investigation</topic><topic>Eye</topic><topic>Eye diseases</topic><topic>Glaucoma</topic><topic>Glaucoma - drug therapy</topic><topic>Humans</topic><topic>Intraocular Pressure</topic><topic>Intravitreal Injections</topic><topic>Japan - epidemiology</topic><topic>Macular degeneration</topic><topic>Macular Degeneration - drug therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Observational studies</topic><topic>Ophthalmology</topic><topic>Patients</topic><topic>Ranibizumab - therapeutic use</topic><topic>Receptors, Vascular Endothelial Growth Factor</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Vascular Endothelial Growth Factor A</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Honjo, Junichiro</creatorcontrib><creatorcontrib>Mukai, Ryo</creatorcontrib><creatorcontrib>Itagaki, Kanako</creatorcontrib><creatorcontrib>Tanaka, Keiichiro</creatorcontrib><creatorcontrib>Norikawa, Koki</creatorcontrib><creatorcontrib>Kato, Yutaka</creatorcontrib><creatorcontrib>Kasai, Akihito</creatorcontrib><creatorcontrib>Sugano, Yukinori</creatorcontrib><creatorcontrib>Sekiryu, Tetsuju</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Honjo, Junichiro</au><au>Mukai, Ryo</au><au>Itagaki, Kanako</au><au>Tanaka, Keiichiro</au><au>Norikawa, Koki</au><au>Kato, Yutaka</au><au>Kasai, Akihito</au><au>Sugano, Yukinori</au><au>Sekiryu, Tetsuju</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intraocular pressure changes during intravitreal aflibercept injection based on treat-and-extend regimen in Japanese patients with neovascular age-related macular degeneration and glaucoma</atitle><jtitle>Japanese journal of ophthalmology</jtitle><stitle>Jpn J Ophthalmol</stitle><addtitle>Jpn J Ophthalmol</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>68</volume><issue>2</issue><spage>91</spage><epage>95</epage><pages>91-95</pages><issn>0021-5155</issn><eissn>1613-2246</eissn><abstract>Purpose
To assess the changes in intraocular pressure (IOP) after intravitreal aflibercept injections in Japanese patients with neovascular age-related macular degeneration (nAMD) complicated by glaucoma.
Study design
Retrospective observational study.
Methods
We retrospectively reviewed 27 eyes of 25 Japanese patients diagnosed with nAMD complicated by glaucoma. The patients were treated with 2 mg/0.05 ml of aflibercept and followed for 52 weeks according to a treat-and-extend (TAE) regimen after 3 consecutive monthly injections. The IOP of each eye was measured at each visit using non-contact tonometry. IOP changes as well as additional glaucoma treatments during 52 weeks were recorded.
Results
The mean of aflibercept injections was 8.3 ± 1.9. The mean IOP at baseline was 14.0 ± 3.1 mmHg, and the mean IOP after aflibercept therapy was 13.0 ± 2.4 mmHg at the final visit (
P
= 0.0463). No patients received additional glaucoma treatment of eye drops or surgery.
Conclusion
Our results suggest that intravitreal aflibercept injections may be beneficial for patients with nAMD complicated by glaucoma.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>38316703</pmid><doi>10.1007/s10384-023-01041-3</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-5155 |
| ispartof | Japanese journal of ophthalmology, 2024-03, Vol.68 (2), p.91-95 |
| issn | 0021-5155 1613-2246 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2922947493 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Age Age related diseases Angiogenesis Inhibitors Clinical Investigation Eye Eye diseases Glaucoma Glaucoma - drug therapy Humans Intraocular Pressure Intravitreal Injections Japan - epidemiology Macular degeneration Macular Degeneration - drug therapy Medicine Medicine & Public Health Observational studies Ophthalmology Patients Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor Recombinant Fusion Proteins - therapeutic use Retrospective Studies Vascular Endothelial Growth Factor A |
| title | Intraocular pressure changes during intravitreal aflibercept injection based on treat-and-extend regimen in Japanese patients with neovascular age-related macular degeneration and glaucoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A37%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intraocular%20pressure%20changes%20during%20intravitreal%20aflibercept%20injection%20based%20on%20treat-and-extend%20regimen%20in%20Japanese%20patients%20with%20neovascular%20age-related%20macular%20degeneration%20and%20glaucoma&rft.jtitle=Japanese%20journal%20of%20ophthalmology&rft.au=Honjo,%20Junichiro&rft.date=2024-03-01&rft.volume=68&rft.issue=2&rft.spage=91&rft.epage=95&rft.pages=91-95&rft.issn=0021-5155&rft.eissn=1613-2246&rft_id=info:doi/10.1007/s10384-023-01041-3&rft_dat=%3Cproquest_cross%3E2985943087%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2985943087&rft_id=info:pmid/38316703&rfr_iscdi=true |